Waters CorpWAT
WAT
About: Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Employees: 7,600
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
297% more call options, than puts
Call options by funds: $9.84M | Put options by funds: $2.48M
29% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 62
2.14% more ownership
Funds ownership: 95.45% [Q1] → 97.6% (+2.14%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 271 | Existing positions reduced: 271
0% less funds holding
Funds holding: 754 [Q1] → 752 (-2) [Q2]
3% less capital invested
Capital invested by funds: $20.9B [Q1] → $20.3B (-$614M) [Q2]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q1] → 8 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$315
5%
upside
Avg. target
$348
17%
upside
High target
$385
29%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
Deutsche Bank Justin Bowers | 5%upside $315 | Hold Maintained | 5 Aug 2025 |
Wells Fargo Brandon Couillard | 5%upside $315 | Equal-Weight Maintained | 5 Aug 2025 |
Jefferies Tycho Peterson | 29%upside $385 | Buy Maintained | 4 Aug 2025 |
Baird Catherine Ramsey | 18%upside $352 | Outperform Maintained | 16 Jul 2025 |
B of A Securities Derik De Bruin | 25%upside $375 | Neutral Maintained | 26 Jun 2025 |
Financial journalist opinion
Based on 7 articles about WAT published over the past 30 days
Neutral
Seeking Alpha
3 weeks ago
Waters Corporation (WAT) Q2 2025 Earnings Call Transcript
Waters Corporation (NYSE:WAT ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Amol Chaubal - Senior VP & CFO Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Sung Ji Nam - Scotiabank Global Banking and Markets, Research Division Tycho W.
Positive
Zacks Investment Research
3 weeks ago
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
Waters (WAT) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.63 per share a year ago.
Positive
The Motley Fool
3 weeks ago
Waters (WAT) Q2 Revenue Jumps 9%
Waters (WAT) Q2 Revenue Jumps 9%
Neutral
PRNewsWire
3 weeks ago
Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05 Second Quarter 2025 MILFORD, Mass. , Aug. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the second quarter of 2025.
Positive
Zacks Investment Research
3 weeks ago
Why Waters (WAT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
4 weeks ago
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Zacks Investment Research
4 weeks ago
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Waters Corporation (NYSE: WAT)
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Waters Corporation (NYSE: WAT ) related to its merger with BD and Company's Biosciences and Diagnostic Solutions. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company. Is it a fair deal?
Neutral
Business Wire
1 month ago
WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company. KSF is seeking to determin.
Positive
Zacks Investment Research
1 month ago
BD Partners With Waters to Build High-Volume Diagnostics Leader
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
Charts implemented using Lightweight Charts™